Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jun 28, 2011


BioNanomatrix has named Todd Dickinson vice president of product development and Xing Yang vice president of system integration. The Philadelphia-based biochip firm made the appointments as part of an expansion that included opening a San Diego office.

Dickinson joins BioNanomatrix from Illumina, where he most recently served as director of product development for its DNA sequencing business. Yang previously worked at Epic Sciences where he served as vice president of technology. He also was president of research for Helixis and director of systems development for BD Diagnostics-GeneOhm.

Sequenom has appointed Charles Slacik to serve on its board of directors. Slacik is currently chief financial officer and senior vice president at Beckman Coulter.

Prior to Beckman, Slacik was executive VP and CFO at Watson Pharmaceuticals and senior VP and CFO at the medical technologies company CR Bard.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.